{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T16:26:13Z","timestamp":1780676773496,"version":"3.54.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012681","name":"Universit\u00e4tsklinikum K\u00f6ln","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012681","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["ICMx"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Critically ill patients are at increased risk for cytomegalovirus (CMV) reactivation, which is associated with poorer clinical outcomes. However, little is known about the longitudinal viremia trajectories in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective single-center study was conducted in a medical ICU and included patients with CMV viremia\u2009\u2265\u20091000 International Units CMV\u2013DNA per milliliter whole blood (IU\/mL) treated between March 2014 and April 2021. Time-series clustering was applied to identify subgroups of patients with similar longitudinal viremia trajectories.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      82 patients were included in the final analysis. Time-series clustering identified three distinct clusters: (1) patients with initial high viremia (median 46,700\u00a0IU\/mL), 94% receiving treatment and showing subsequent steep reduction of viremia; (2) patients with moderate viremia (median 2720\u00a0IU\/mL) and subsequent increase in viral load, treated in 52%; and (3) patients with moderate viremia (median 3120\u00a0IU\/mL), 63% receiving treatment and showing stable viral load in follow-up measurements. No significant differences were identified between the clusters with respect to patient characteristics, including underlying immunosuppression. With respect to disease severity, the Acute Physiology and Chronic Health Evaluation II (APACHE-II) score was highest in cluster 3 and among patients without follow-up CMV\u2013DNA measurements (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.029), while the Sequential Organ Failure Assessment (SOFA) score demonstrated a similar directional trend without reaching statistical significance. Survival differed significantly between the clusters in the Kaplan\u2013Meier estimate (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.008); however, absolute 1-year survival was low across all clusters (cluster 1: 0%, cluster 2: 33%, cluster 3: 32%, patients without follow-up CMV measurement: 14%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.062). Probable CMV pneumonia with respiratory symptoms and CMV\u2013DNA detection in bronchoalveolar lavage fluid was the most common disease manifestation (cluster 1: 35%; cluster 2: 28%; cluster 3: 7.5%; patients without follow-up CMV measurement: 23%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.040).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this hypothesis-generating study, time-series clustering analysis identified three subgroups with distinct longitudinal viremia trajectories which significantly differed in viral load, treatment decisions and survival over time. The diagnostic and therapeutic relevance of longitudinal CMV viremia trajectories and the optimal CMV\u2013DNA threshold for treatment initiation in ICU patients remain undefined and might differ from other cohorts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40635-026-00866-9","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T06:45:13Z","timestamp":1770878713000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Time-series clustering analysis reveals distinct patterns of cytomegalovirus viremia in critically ill adults"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6420-7938","authenticated-orcid":false,"given":"Jan-Hendrik","family":"Naendrup","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver Martin","family":"Hilbers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Gruell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Altenrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Michel","family":"Heger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis Alexander","family":"Eichenauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"B\u00f6ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Kochanek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Shimabukuro-Vornhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Garcia Borrega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"issue":"3","key":"866_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2034","volume":"29","author":"M Zuhair","year":"2019","unstructured":"Zuhair M, Smit GSA, Wallis G et al (2019) Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta-analysis. Rev Med Virol 29(3):e2034. https:\/\/doi.org\/10.1002\/rmv.2034","journal-title":"Rev Med Virol"},{"issue":"1","key":"866_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-022-13971-7","volume":"22","author":"K Fowler","year":"2022","unstructured":"Fowler K, Mucha J, Neumann M et al (2022) A systematic literature review of the global seroprevalence of cytomegalovirus: possible implications for treatment, screening, and vaccine development. BMC Public Health 22(1):1659. https:\/\/doi.org\/10.1186\/s12889-022-13971-7","journal-title":"BMC Public Health"},{"key":"866_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.00130","volume":"10","author":"E Forte","year":"2020","unstructured":"Forte E, Zhang Z, Thorp EB, Hummel M (2020) Cytomegalovirus latency and reactivation: an intricate interplay with the host immune response. Front Cell Infect Microbiol 10:523262. https:\/\/doi.org\/10.3389\/fcimb.2020.00130","journal-title":"Front Cell Infect Microbiol"},{"issue":"Suppl 1","key":"866_CR4","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.1093\/infdis\/jiz638","volume":"221","author":"H Imlay","year":"2020","unstructured":"Imlay H, Limaye AP (2020) Current understanding of cytomegalovirus reactivation in critical illness. J Infect Dis 221(Suppl 1):S94\u2013S102. https:\/\/doi.org\/10.1093\/infdis\/jiz638","journal-title":"J Infect Dis"},{"issue":"12","key":"866_CR5","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41579-021-00582-z","volume":"19","author":"P Griffiths","year":"2021","unstructured":"Griffiths P, Reeves M (2021) Pathogenesis of human cytomegalovirus in the immunocompromised host. Nat Rev Microbiol 19(12):759\u2013773. https:\/\/doi.org\/10.1038\/s41579-021-00582-z","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"866_CR6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s00134-015-4066-9","volume":"42","author":"L Papazian","year":"2016","unstructured":"Papazian L, Hraiech S, Lehingue S et al (2016) Cytomegalovirus reactivation in ICU patients. Intensive Care Med 42(1):28\u201337. https:\/\/doi.org\/10.1007\/s00134-015-4066-9","journal-title":"Intensive Care Med"},{"issue":"3","key":"866_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/J.DIAGMICROBIO.2025.116967","volume":"113","author":"A Zouaki","year":"2025","unstructured":"Zouaki A, Abidi K, Seffar M et al (2025) Cytomegalovirus reactivation among immunocompetent patients hospitalized in medical intensive care: associated factors and consequences. Diagn Microbiol Infect Dis 113(3):116967. https:\/\/doi.org\/10.1016\/J.DIAGMICROBIO.2025.116967","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"866_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-025-05324-8","volume":"29","author":"JY Kim","year":"2025","unstructured":"Kim JY, Lee CM, Ahn YH et al (2025) Cytomegalovirus reactivation in the lower respiratory tract as an independent risk factor for mortality in critically ill patients. Crit Care 29(1):177. https:\/\/doi.org\/10.1186\/s13054-025-05324-8","journal-title":"Crit Care"},{"key":"866_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2024.154766","volume":"82","author":"A Baber","year":"2024","unstructured":"Baber A, Calvet L, Vissac C et al (2024) Cytomegalovirus infection in intensive care unit patients with hematological malignancies: characteristics and clinical outcomes. J Crit Care 82:154766. https:\/\/doi.org\/10.1016\/j.jcrc.2024.154766","journal-title":"J Crit Care"},{"key":"866_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00188","volume":"7","author":"J Schildermans","year":"2020","unstructured":"Schildermans J, De Vlieger G (2020) Cytomegalovirus: a troll in the ICU? Overview of the literature and perspectives for the future. Front Med 7:515027. https:\/\/doi.org\/10.3389\/fmed.2020.00188","journal-title":"Front Med"},{"issue":"9","key":"866_CR11","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1177\/08850666211053990","volume":"37","author":"JH Naendrup","year":"2022","unstructured":"Naendrup JH, Garcia Borrega J, Eichenauer DA, Shimabukuro-Vornhagen A, Kochanek M, B\u00f6ll B (2022) Reactivation of EBV and CMV in severe COVID-19-epiphenomena or trigger of hyperinflammation in need of treatment? A large case series of critically ill patients. J Intensive Care Med 37(9):1152\u20131158. https:\/\/doi.org\/10.1177\/08850666211053990","journal-title":"J Intensive Care Med"},{"issue":"2","key":"866_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005133.pub3","volume":"2013","author":"DS Owers","year":"2013","unstructured":"Owers DS, Webster AC, Strippoli GFM, Kable K, Hodson EM (2013) Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2013(2):CD005133. https:\/\/doi.org\/10.1002\/14651858.CD005133.pub3","journal-title":"Cochrane Database Syst Rev"},{"issue":"19","key":"866_CR13","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1182\/blood.2019000956","volume":"135","author":"H Einsele","year":"2020","unstructured":"Einsele H, Ljungman P, Boeckh M (2020) How i treat CMV reactivation after allogeneic hematopoietic stem cell transplantation. Blood 135(19):1619\u20131629. https:\/\/doi.org\/10.1182\/blood.2019000956","journal-title":"Blood"},{"issue":"1","key":"866_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-020-00793-2","volume":"11","author":"L Papazian","year":"2021","unstructured":"Papazian L, Jaber S, Hraiech S et al (2021) Preemptive ganciclovir for mechanically ventilated patients with cytomegalovirus reactivation. Ann Intensive Care 11(1):33. https:\/\/doi.org\/10.1186\/s13613-020-00793-2","journal-title":"Ann Intensive Care"},{"issue":"8","key":"866_CR15","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1001\/jama.2017.10569","volume":"318","author":"AP Limaye","year":"2017","unstructured":"Limaye AP, Stapleton RD, Peng L et al (2017) Effect of ganciclovir on IL-6 levels among cytomegalovirus-seropositive adults with critical illness: a randomized clinical trial. JAMA 318(8):731\u2013740. https:\/\/doi.org\/10.1001\/jama.2017.10569","journal-title":"JAMA"},{"issue":"1","key":"866_CR16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/cid\/ciw668","volume":"64","author":"P Ljungman","year":"2017","unstructured":"Ljungman P, Boeckh M, Hirsch HH et al (2017) Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials: Table 1. Clin Infect Dis 64(1):87\u201391. https:\/\/doi.org\/10.1093\/cid\/ciw668","journal-title":"Clin Infect Dis"},{"issue":"4","key":"866_CR17","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.bbmt.2017.11.038","volume":"24","author":"JF Camargo","year":"2018","unstructured":"Camargo JF, Kimble E, Rosa R et al (2018) Impact of cytomegalovirus viral load on probability of spontaneous clearance and response to preemptive therapy in allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant 24(4):806\u2013814. https:\/\/doi.org\/10.1016\/j.bbmt.2017.11.038","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"866_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/tid.14318","volume":"26","author":"K Soliman","year":"2024","unstructured":"Soliman K, Calimlim IK, Perry A et al (2024) Evolving trends in immunosuppression use and cytomegalovirus infection risk over the past decade in kidney transplantation. Transpl Infect Dis 26(5):e14318. https:\/\/doi.org\/10.1111\/tid.14318","journal-title":"Transpl Infect Dis"},{"issue":"8","key":"866_CR19","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1111\/J.1600-6143.2010.03114.X","volume":"10","author":"A \u00c5sberg","year":"2010","unstructured":"\u00c5sberg A, Jardine AG, Bignamini AA et al (2010) Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients. Am J Transplant 10(8):1881\u20131888. https:\/\/doi.org\/10.1111\/J.1600-6143.2010.03114.X","journal-title":"Am J Transplant"},{"issue":"2","key":"866_CR20","doi-asserted-by":"publisher","first-page":"174","DOI":"10.36519\/idcm.2025.480","volume":"7","author":"HC \u00c7imenda\u011f","year":"2025","unstructured":"\u00c7imenda\u011f HC, Say\u0131ner A, G\u00f6kmen AN, Avkan-O\u011fuz V (2025) Risk factors for cytomegalovirus reactivation and its impact on clinical outcomes in immunocompetent seropositive patients admitted to the intensive care unit: a single-center prospective observational study. Infect Dis Clin Microbiol 7(2):174\u2013184. https:\/\/doi.org\/10.36519\/idcm.2025.480","journal-title":"Infect Dis Clin Microbiol"},{"issue":"1","key":"866_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-016-0207-8","volume":"6","author":"A Al-Omari","year":"2016","unstructured":"Al-Omari A, Aljamaan F, Alhazzani W, Salih S, Arabi Y (2016) Cytomegalovirus infection in immunocompetent critically ill adults: literature review. Ann Intensive Care 6(1):110. https:\/\/doi.org\/10.1186\/s13613-016-0207-8","journal-title":"Ann Intensive Care"},{"key":"866_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1600289","volume":"16","author":"S Dobrer","year":"2025","unstructured":"Dobrer S, Sherwood KR, Davis K et al (2025) Impact of viral load kinetics and recurrent cytomegalovirus infection in kidney transplantation. Front Immunol 16:1600289. https:\/\/doi.org\/10.3389\/fimmu.2025.1600289","journal-title":"Front Immunol"},{"issue":"7","key":"866_CR23","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1093\/cid\/ciac892","volume":"76","author":"M Fang","year":"2023","unstructured":"Fang M, Lin X, Wang C et al (2023) High cytomegalovirus viral load is associated with 182-day all-cause mortality in hospitalized people with human immunodeficiency virus. Clin Infect Dis 76(7):1266\u20131275. https:\/\/doi.org\/10.1093\/cid\/ciac892","journal-title":"Clin Infect Dis"},{"key":"866_CR24","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.ijid.2022.07.035","volume":"122","author":"CP Skipper","year":"2022","unstructured":"Skipper CP, Hullsiek KH, Cresswell FV et al (2022) Cytomegalovirus viremia as a risk factor for mortality in HIV-associated cryptococcal and tuberculous meningitis. Int J Infect Dis 122:785\u2013792. https:\/\/doi.org\/10.1016\/j.ijid.2022.07.035","journal-title":"Int J Infect Dis"},{"issue":"3","key":"866_CR25","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","volume":"3","author":"ML Green","year":"2016","unstructured":"Green ML, Leisenring W, Xie H et al (2016) Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol 3(3):e119\u2013e127. https:\/\/doi.org\/10.1016\/S2352-3026(15)00289-6","journal-title":"Lancet Haematol"},{"issue":"4","key":"866_CR26","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/j.1600-6143.2004.00391.x","volume":"4","author":"A Humar","year":"2004","unstructured":"Humar A, Paya C, Pescovitz MD et al (2004) Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+\/R- solid organ transplant recipients. Am J Transplant 4(4):644\u2013649. https:\/\/doi.org\/10.1111\/j.1600-6143.2004.00391.x","journal-title":"Am J Transplant"},{"issue":"9","key":"866_CR27","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1097\/00007890-199911150-00015","volume":"68","author":"A Humar","year":"1999","unstructured":"Humar A, Gregson D, Caliendo AM et al (1999) Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients. Transplantation 68(9):1305\u20131311. https:\/\/doi.org\/10.1097\/00007890-199911150-00015","journal-title":"Transplantation"},{"issue":"6","key":"866_CR28","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/sj.bmt.1701139","volume":"21","author":"D Gor","year":"1998","unstructured":"Gor D, Sabin C, Prentice H et al (1998) Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor\/recipient serostatus, acute GVHD and CMV disease. Bone Marrow Transplant 21(6):597\u2013605. https:\/\/doi.org\/10.1038\/sj.bmt.1701139","journal-title":"Bone Marrow Transplant"},{"key":"866_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae321","volume":"16","author":"P Ljungman","year":"2024","unstructured":"Ljungman P, Chemaly RF, Khawaya F et al (2024) Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum. Clin Infect Dis 16:19. https:\/\/doi.org\/10.1093\/cid\/ciae321","journal-title":"Clin Infect Dis"},{"issue":"5","key":"866_CR30","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1093\/infdis\/jiad386","volume":"229","author":"A Sadowska-Klasa","year":"2024","unstructured":"Sadowska-Klasa A, Leisenring WM, Limaye AP, Boeckh M (2024) Cytomegalovirus viral load threshold to guide preemptive therapy in hematopoietic cell transplant recipients: correlation with cytomegalovirus disease. J Infect Dis 229(5):1435\u20131439. https:\/\/doi.org\/10.1093\/infdis\/jiad386","journal-title":"J Infect Dis"},{"issue":"9","key":"866_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0163722","volume":"11","author":"PD Griffiths","year":"2016","unstructured":"Griffiths PD, Rothwell E, Raza M et al (2016) Randomized controlled trials to define viral load thresholds for cytomegalovirus pre-emptive therapy. PLoS ONE 11(9):e0163722. https:\/\/doi.org\/10.1371\/journal.pone.0163722","journal-title":"PLoS ONE"},{"issue":"1","key":"866_CR32","doi-asserted-by":"publisher","first-page":"4870","DOI":"10.1182\/blood-2024-207700","volume":"144","author":"S Fujiwara","year":"2024","unstructured":"Fujiwara S, Kawamura S, Kimura SI et al (2024) Appropriate threshold of quantitative cytomegalovirus DNA polymerase chain reaction for preemptive treatment in stem cell transplant recipients. Blood 144(1):4870\u20134870. https:\/\/doi.org\/10.1182\/blood-2024-207700","journal-title":"Blood"}],"container-title":["Intensive Care Medicine Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40635-026-00866-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40635-026-00866-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40635-026-00866-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T06:45:14Z","timestamp":1770878714000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40635-026-00866-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["866"],"URL":"https:\/\/doi.org\/10.1186\/s40635-026-00866-9","relation":{},"ISSN":["2197-425X"],"issn-type":[{"value":"2197-425X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Prior to the start of the study, approval was obtained by the local ethics committee of the Faculty of Medicine of the University of Cologne (approval number: 24\u20131308-retro). Given the non-interventional retrospective nature of the study no informed consent had to be obtained from the included patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JHN received research funding from the Else Kr\u00f6ner-Fresenius-Stiftung for research on ECMO-induced coagulopathy, not related to the submitted work. BB has served as a consultant or advisor for AMGEN, Astellas, AstraZeneca, Autolous, Kite\/Gilead, Miltenyi, MSD Sharp and Dohme, Noscendo, and has received honoraria from Amgen, Astellas, Kite\/Gilead, Pfizer, and Roche\u2014all outside of the submitted work. JGB received scientific grants from Kite\/Gilead not related to the submitted manuscript. OMH, HG, LA, JMH, DAE, MK and ASV declare that they have no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"16"}}